Log in

NASDAQ:TORCresTORbio Stock Price, Forecast & News

$2.31
+0.03 (+1.32 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.23
Now: $2.31
$2.32
50-Day Range
$2.12
MA: $2.43
$2.99
52-Week Range
$0.86
Now: $2.31
$11.00
Volume288,791 shs
Average Volume1.26 million shs
Market Capitalization$84.21 million
P/E RatioN/A
Dividend YieldN/A
Beta2.61
resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.
Read More
resTORbio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TORC
CUSIPN/A
Phone857-315-5528

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.24 per share

Profitability

Net Income$-82,740,000.00

Miscellaneous

EmployeesN/A
Market Cap$84.21 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$2.31
+0.03 (+1.32 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TORC News and Ratings via Email

Sign-up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











resTORbio (NASDAQ:TORC) Frequently Asked Questions

How has resTORbio's stock price been impacted by Coronavirus?

resTORbio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TORC stock has increased by 97.4% and is now trading at $2.31.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of resTORbio?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for resTORbio
.

When is resTORbio's next earnings date?

resTORbio is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for resTORbio
.

How were resTORbio's earnings last quarter?

resTORbio, Inc. (NASDAQ:TORC) released its earnings results on Thursday, July, 30th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07.
View resTORbio's earnings history
.

What price target have analysts set for TORC?

6 equities research analysts have issued 1-year price targets for resTORbio's stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate resTORbio's share price to reach $3.50 in the next year. This suggests a possible upside of 51.5% from the stock's current price.
View analysts' price targets for resTORbio
.

Has resTORbio been receiving favorable news coverage?

Press coverage about TORC stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. resTORbio earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about resTORbio
.

Are investors shorting resTORbio?

resTORbio saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 560,900 shares, a decrease of 24.7% from the June 15th total of 744,700 shares. Based on an average trading volume of 1,460,000 shares, the short-interest ratio is presently 0.4 days. Approximately 2.6% of the shares of the company are short sold.
View resTORbio's Short Interest
.

Who are some of resTORbio's key competitors?

What other stocks do shareholders of resTORbio own?

Who are resTORbio's key executives?

resTORbio's management team includes the following people:
  • Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 47)
  • Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 60)
  • Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 51)
  • Ms. Jennifer Robinson, Sr. Director of Investor Relations & Corp. Communication
  • Dr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 69)

When did resTORbio IPO?

(TORC) raised $86 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is resTORbio's stock symbol?

resTORbio trades on the NASDAQ under the ticker symbol "TORC."

Who are resTORbio's major shareholders?

resTORbio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (7.97%), Ikarian Capital LLC (3.98%), Artal Group S.A. (2.61%), Anson Funds Management LP (1.06%), Goldman Sachs Group Inc. (0.24%) and Edge Wealth Management LLC (0.15%).
View institutional ownership trends for resTORbio
.

Which major investors are selling resTORbio stock?

TORC stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, and Algert Global LLC.
View insider buying and selling activity for resTORbio
.

Which major investors are buying resTORbio stock?

TORC stock was acquired by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Ikarian Capital LLC, Artal Group S.A., Anson Funds Management LP, Edge Wealth Management LLC, Goldman Sachs Group Inc., Virtu Financial LLC, and Strategic Wealth Designers.
View insider buying and selling activity for resTORbio
.

How do I buy shares of resTORbio?

Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is resTORbio's stock price today?

One share of TORC stock can currently be purchased for approximately $2.31.

How big of a company is resTORbio?

resTORbio has a market capitalization of $84.21 million. The company earns $-82,740,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

What is resTORbio's official website?

The official website for resTORbio is www.restorbio.com.

How can I contact resTORbio?

resTORbio's mailing address is 500 BOYLSTON STREET 13TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5528.

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.